Roche Diagnostics Australia Pty Ltd

  Roche, a global leader in in-vitro diagnostics and personalised healthcare, is expanding the sequencing ecosystem with the forthcoming AXELIOS 1 platform. This platform features the disruptive Sequencing by Expansion (SBX) technology, which overcomes traditional signal-to-noise limitations. AXELIOS 1 aims to provide ultra-rapid, scalable and flexible read sequencing for a diverse range of research applications. The sequencing portfolio is complemented by high-performance KAPA sample prep products and the automated AVENIO Edge system.